See the DrugPatentWatch profile for vyvanse
Vyvanse is owned by Takeda Pharmaceutical Company [1]. Originally developed by Shire, Takeda acquired Shire in 2019, thereby acquiring ownership of Vyvanse [1][2].
When Did Takeda Acquire Shire?
Takeda completed its acquisition of Shire in January 2019 [2]. This move integrated Shire's portfolio, including Vyvanse, into Takeda's global operations [2].
What is Vyvanse Used For?
Vyvanse is a prescription medication used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adults [3]. It is also approved for the treatment of moderate to severe binge-eating disorder (BED) in adults [3].
What is the Generic Name for Vyvanse?
The generic name for Vyvanse is lisdexamfetamine [3]. Lisdexamfetamine is a prodrug of dextroamphetamine, meaning it is converted to dextroamphetamine in the body [4].
When Does Vyvanse Go Off-Patent?
Information regarding the specific patent expiry dates for Vyvanse is available through resources like DrugPatentWatch.com [5]. These dates are crucial for understanding when generic versions of the drug may become available.
Can Generic Vyvanse Be Made Now?
The availability of generic versions of Vyvanse depends on patent expiry and any associated exclusivity periods [5]. If patents have expired and no further exclusivity remains, generic manufacturers may be able to produce and market their versions of the drug.
Who Manufactures Vyvanse?
Takeda Pharmaceutical Company is the current owner and manufacturer of Vyvanse [1][2]. Before the acquisition, Shire was the original developer and manufacturer.